Bionano Genomics Stock News

In todays recent session, 1.74 million shares of the Bionano Genomics Inc. (NASDAQ:BNGO) have been traded, and its beta is 1.91. Most recently the companys share price was $2.15, and it changed around -$0.04 or -1.60% from the last close, which brings the market valuation of the company to $676.71M. BNGO at last check was Bionano Genomics Inc. (NASDAQ: BNGO) Shares Might Go Down -84.01% This Year Read More »

SAN DIEGO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical, the leading software solution for visualization, interpretation and reporting of genomic data, announced today that company management will present virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. Erik Holmlin, PhD, Bionanos president and chief executive officer, is scheduled to participate in a fireside chat on Wednesday, February 16th, 2022 at 2:30 pm ET. BTIG hosted events are intended for prospective and existing BTIG clients. To listen to the live event, please contact your BTIG representative with interest.

SAN DIEGO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading softwa

InvestorPlace - Stock Market News, Stock Advice & Trading Tips A preliminary report from Bionano Genomics doesn''t tell the full story and a lack of profitability will likely weigh on BNGO stock. The post Investors Have Cast Their No Votes Against Bionano Genomics appeared first on InvestorPlace . More From InvestorPlace Stock Prodigy Who Found NIO at $2 Says Buy THIS Now Man Who Called Black Monday: Prepare Now. #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First

A preliminary report from Bionano Genomics doesn't tell the full story and a lack of profitability will likely weigh on BNGO stock. The post Investors Have Cast Their ‘No' Votes Against Bionano Geno

Bionano's recent results are lackluster and point to more volatility ahead for BNGO stock. Best to just avoid this stock for now.

Bionano Stock: The Delicate Balance Between Growth And Share Dilution

Bionano Genomics <> announced the adoption of its Saphyr system by two genetics laboratory hubs ((GLH)) within the U.K.''s National Health Service ((NHS)).The Newcastle upon

Select analysts and investment banks believe these little-known companies can skyrocket.

BNGO Stock is a play in the burgeoning gene sequencing market at scale, not at home. That's worth understanding and potentially purchasing.

Bionano (BNGO) is a company focused on disrupting the cytogenetics space and it has been taking meaningful strides toward that goal over the past year. Last week, t

Average daily attendance of 565 in 2022 versus 346 in 2021 Over 4,000 registrants with attendees represented from 82 countries 31 oral presentations delivered across four consecutive days 37 scientific posters featuring OGM in the online exhibit hall On-demand presentations from Symposium available for remainder of 2022 SAN DIEGO, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical, the leading software solutions for visualization, interpretation and reporting of genomic data, today announced the conclusion of Bionano''s 2022 Symposium, with record daily attendance representing a 63% increase relative to last year''s event. Bionano''s premier scientific event showcasing OGM, Symposium was held January 10-13, 2022. Symposium had over 4,000 registrants from 82 countries and featured 31 oral presentations and 37 scientific posters from genomic scientists at leading institutions, including Brigham and Women''s Hospital, MD Anderson Cancer Center, and Quest Diagnostics.

Bionano Genomics Inc (BNGO) shares closed today at 1.2% above its 52 week low of $2.52, giving the company a market cap of $734M. The stock is currently down 15.1% year-to-date, down 54.9% over the past 12 months, and down 63.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 0.7%. Trading Activity Trading volume this week was 40.2% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -6.6% The company's stock price performance over the past 12 months lags the peer average by 64.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

This time last year, shares of Bionano Genomics (BNGO) were in the midst of one almighty tear, as the market seized upon the opportunity of its optical genome mappi

SAN DIEGO, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical, the leading software solutions for visualization, interpretation and reporting of genomic data, hosted the third day of 2022 Symposium, the Company''s premiere event showcasing OGM research applications across key clinical areas of constitutional genetic disease, hematologic malignancies, solid tumors and OGM combined with next-generation sequencing (NGS). Seven presentations from leading researchers across North America and Europe showcased the utility of OGM for analysis of solid tumors at 2022 Symposium. Seven presentations from experts across North America and Europe shared how OGM can characterize genetic aberrations in a wide variety of cancers, such as pediatric brain tumors, pulmonary mesothelioma and many others. Their findings consistently demonstrated high concordance of OGM results for structural variants (SVs) identified by traditional cytogenetic and molecular methods.